<DOC>
	<DOCNO>NCT00344552</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-181339 shrink slow growth cancer patient advance recurrent esophageal cancer . The safety treatment also study .</brief_summary>
	<brief_title>Phase II Study Weekly Paclitaxel ( BMS-181339 ) Patients With Advanced Recurrent Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients must measurable disease Patients must experience pervious chemotherapy regime Men Women , age 20 year old ECOG PS : 01 Patients previous therapy Taxanes</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>